VERACYTE, INC. (VCYT)

Latest Insider Confidence Score

2026Q1

46.8
Bearish

Company insider confidence (by quarter)

2013Q4 2026Q1

Largest shareholders

Insider Role (last 12 mo) Shares held Filed at
Kleiner Perkins Caufield & Byers XII, Llc — 2,801,929 Mar 14, 2017
KPCB XII Founders Fund, LLC — 2,801,929 Mar 14, 2017
KPCB XII Associates, LLC — 2,801,929 Mar 14, 2017
Vitullo Nicole — 2,763,294 Sep 12, 2014
Blair James C — 2,763,294 Sep 12, 2014

Recent buy/sell transactions

Exec date Filing date Insider Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Mar 4, 2026 Mar 6, 2026 Chambers Rebecca CFO Sell 25.0 -18,341 -12.27% ✓ $662.9K
Mar 4, 2026 Mar 6, 2026 Stapley Marc CEO Sell 23.8 -45,523 -11.29% ✓ $1.6M
Mar 4, 2026 Mar 6, 2026 Leite John Chief Commercial Officer-CLIA Sell 38.8 -5,260 -4.66% ✓ $185.1K
Mar 4, 2026 Mar 6, 2026 McGuire Annie SVP, General Counsel Sell 33.8 -6,658 -6.57% ✓ $236.7K
Mar 2, 2026 Mar 4, 2026 McGuire Annie SVP, General Counsel Sell 42.5 -6,902 -6.38% ✗ $248.5K
Mar 2, 2026 Mar 4, 2026 Wygant Jonathan VP, Chief Accounting Officer Sell 42.5 -3,006 -7.93% ✗ $108.2K
Mar 2, 2026 Mar 4, 2026 Chambers Rebecca CFO Sell 40.0 -7,234 -4.61% ✗ $260.5K
Mar 2, 2026 Mar 4, 2026 Leite John Chief Commercial Officer-CLIA Sell 40.0 -7,517 -6.25% ✗ $270.7K
Mar 2, 2026 Mar 4, 2026 Febbo Phillip G. Chief Scientific & Med Officer Sell 25.0 -19,460 -14.22% ✓ $702.7K
Mar 2, 2026 Mar 4, 2026 Stapley Marc CEO Sell 40.0 -19,455 -4.60% ✗ $700.6K
Feb 26, 2026 Mar 2, 2026 Leite John Chief Commercial Officer-CLIA Sell 97.5 +38,244 46.57% ✗ $345.1K
Feb 26, 2026 Mar 2, 2026 Stapley Marc CEO Sell 100.0 +103,233 32.33% ✗ $1.4M
Feb 26, 2026 Mar 2, 2026 Chambers Rebecca CFO Sell 97.5 +47,275 43.18% ✗ $466.9K
Feb 26, 2026 Mar 2, 2026 Febbo Phillip G. Chief Scientific & Med Officer Sell 97.5 +47,320 52.88% ✗ $948.8K
Feb 26, 2026 Mar 2, 2026 McGuire Annie SVP, General Counsel Sell 97.5 +40,132 58.90% ✗ $421.1K
Dec 16, 2025 Dec 17, 2025 McGuire Annie SVP, General Counsel Sell 22.5 -10,739 -13.68% ✓ $463.2K
Dec 5, 2025 Dec 8, 2025 EASTHAM KARIN Director Sell 7.5 -20,000 -59.61% ✓ $908.9K
Dec 2, 2025 Dec 4, 2025 Febbo Phillip G. Chief Scientific & Med Officer Sell 42.5 -2,955 -3.20% ✗ $136.4K
Dec 2, 2025 Dec 4, 2025 McGuire Annie SVP, General Counsel Sell 32.5 -4,474 -5.39% ✓ $208.1K
Dec 2, 2025 Dec 4, 2025 Chambers Rebecca CFO Sell 22.5 -16,662 -13.21% ✓ $778.2K
Dec 2, 2025 Dec 4, 2025 Stapley Marc CEO Sell 35.0 -15,582 -4.66% ✓ $726.4K
Dec 2, 2025 Dec 4, 2025 Leite John Chief Commercial Officer-CLIA Sell 37.5 -4,178 -4.84% ✓ $194.6K
Dec 2, 2025 Dec 4, 2025 Wygant Jonathan VP, Chief Accounting Officer Sell 42.5 -1,325 -3.42% ✗ $61.2K
Nov 25, 2025 Nov 26, 2025 Leite John Chief Commercial Officer-CLIA Sell 37.5 -2,808 -3.15% ✓ $140.4K
Nov 25, 2025 Nov 26, 2025 JONES EVAN/ FA Director Sell 37.5 -1,106 -3.63% ✓ $55.6K
Nov 20, 2025 Nov 21, 2025 Holstein Jens Director Sell 7.5 -10,000 -26.88% ✓ $423.6K
Nov 7, 2025 Nov 12, 2025 Wygant Jonathan VP, Chief Accounting Officer Sell 20.0 -10,920 -21.99% ✗ $449.9K
Nov 5, 2025 Nov 7, 2025 McGuire Annie SVP, General Counsel Sell 30.0 -6,466 -7.23% ✓ $258.6K
Nov 5, 2025 Nov 7, 2025 JONES EVAN/ FA Director Sell 5.0 -43,196 -58.64% ✓ $1.9M
Nov 5, 2025 Nov 7, 2025 EASTHAM KARIN Director Sell 7.5 -9,674 -41.65% ✓ $387.2K
Nov 5, 2025 Nov 7, 2025 Chambers Rebecca CFO Sell 30.0 -7,000 -5.26% ✓ $287K
Oct 28, 2025 Oct 30, 2025 Wygant Jonathan VP, Chief Accounting Officer Neutral 85.0 +2,886 6.17% ✗ -
Oct 6, 2025 Oct 7, 2025 Febbo Phillip G. Chief Scientific & Med Officer Sell 26.3 -8,349 -8.28% ✓ $300.7K
Oct 1, 2025 Oct 3, 2025 Leite John Chief Commercial Officer-CLIA Sell 41.3 -2,539 -2.77% ✓ $88.9K
Oct 1, 2025 Oct 3, 2025 EPSTEIN ROBERT S Director Sell 7.5 -21,473 -25.59% ✓ $753.2K
Oct 1, 2025 Oct 3, 2025 McGuire Annie SVP, General Counsel Sell 41.3 -2,160 -2.36% ✓ $75.6K
Sep 19, 2025 Sep 23, 2025 McGuire Annie SVP, General Counsel Sell 41.3 -2,283 -2.43% ✓ $76.9K
Sep 4, 2025 Sep 8, 2025 Stapley Marc CEO Sell 41.3 -7,667 -2.24% ✓ $233.1K
Sep 2, 2025 Sep 4, 2025 Chambers Rebecca CFO Sell 42.5 -5,371 -3.88% ✗ $161.7K
Sep 2, 2025 Sep 4, 2025 McGuire Annie SVP, General Counsel Sell 42.5 -3,507 -3.60% ✗ $105.6K
Sep 2, 2025 Sep 4, 2025 Stapley Marc CEO Sell 42.5 -7,914 -2.26% ✗ $238.3K
Sep 2, 2025 Sep 4, 2025 Febbo Phillip G. Chief Scientific & Med Officer Sell 42.5 -2,955 -2.85% ✗ $89K
Sep 2, 2025 Sep 4, 2025 Leite John Chief Commercial Officer-CLIA Sell 42.5 -2,902 -3.07% ✗ $87.4K
Sep 2, 2025 Sep 4, 2025 Wygant Jonathan VP, Chief Accounting Officer Sell 46.3 -1,648 -3.40% ✗ $49.6K
Jun 18, 2025 Jun 23, 2025 EASTHAM KARIN Director Neutral 90.0 +9,321 67.02% ✗ -
Jun 18, 2025 Jun 23, 2025 Holstein Jens Director Neutral 90.0 +9,321 33.43% ✗ -
Jun 18, 2025 Jun 23, 2025 JONES EVAN/ FA Director Neutral 90.0 +9,321 27.14% ✗ -
Jun 18, 2025 Jun 23, 2025 EPSTEIN ROBERT S Director Neutral 90.0 +9,321 14.43% ✗ -
Jun 18, 2025 Jun 23, 2025 Barr Eliav Director Neutral 90.0 +9,321 22.26% ✗ -
Jun 18, 2025 Jun 23, 2025 Bhanji Muna Director Neutral 90.0 +9,321 31.08% ✗ -
Jun 18, 2025 Jun 23, 2025 Miller Thomas F. Director Neutral 90.0 +9,321 56.47% ✗ -
Jun 18, 2025 Jun 23, 2025 Shafer David Brent Director Neutral 90.0 +9,321 56.47% ✗ -
Jun 13, 2025 Jun 17, 2025 EASTHAM KARIN Director Sell 15.0 -4,590 -24.81% ✓ $122.4K
Jun 13, 2025 Jun 17, 2025 Bhanji Muna Director Sell 25.0 -4,589 -13.27% ✓ $122.4K
Jun 4, 2025 Jun 6, 2025 Leite John Chief Commercial Officer-CLIA Sell 41.3 -2,809 -2.89% ✓ $76.4K
Jun 2, 2025 Jun 4, 2025 McGuire Annie SVP, General Counsel Sell 42.5 -3,505 -3.49% ✗ $93.7K
Jun 2, 2025 Jun 4, 2025 Chambers Rebecca CFO Sell 42.5 -5,370 -3.73% ✗ $143.6K
Jun 2, 2025 Jun 4, 2025 Leite John Chief Commercial Officer-CLIA Sell 42.5 -2,900 -2.89% ✗ $77.5K
Jun 2, 2025 Jun 4, 2025 Wygant Jonathan VP, Chief Accounting Officer Sell 46.3 -1,848 -3.71% ✗ $49.4K
Jun 2, 2025 Jun 4, 2025 Febbo Phillip G. Chief Scientific & Med Officer Sell 42.5 -2,955 -2.77% ✗ $79K
Jun 2, 2025 Jun 4, 2025 Stapley Marc CEO Sell 40.0 -9,399 -2.62% ✗ $251.3K
Mar 6, 2025 Mar 10, 2025 Wygant Jonathan VP, Chief Accounting Officer Neutral 90.0 +13,288 36.43% ✗ -
Mar 6, 2025 Mar 10, 2025 Febbo Phillip G. Chief Scientific & Med Officer Neutral 90.0 +24,160 29.27% ✗ -
Mar 6, 2025 Mar 10, 2025 Chambers Rebecca CFO Neutral 90.0 +30,200 26.56% ✗ -
Mar 6, 2025 Mar 10, 2025 Leite John Chief Commercial Officer-CLIA Sell 95.0 +28,829 40.37% ✓ $234.6K
Mar 6, 2025 Mar 10, 2025 McGuire Annie SVP, General Counsel Neutral 90.0 +30,200 42.95% ✗ -
Mar 6, 2025 Mar 10, 2025 Stapley Marc CEO Neutral 90.0 +90,601 33.80% ✗ -
Mar 4, 2025 Mar 6, 2025 Febbo Phillip G. Chief Scientific & Med Officer Sell 26.3 -8,037 -8.87% ✓ $268K
Mar 4, 2025 Mar 6, 2025 Stapley Marc CEO Sell 15.0 -52,697 -16.43% ✓ $1.8M
Mar 4, 2025 Mar 6, 2025 McGuire Annie SVP, General Counsel Sell 48.8 -1,142 -1.60% ✓ $38.5K
Feb 27, 2025 Mar 3, 2025 Leite John Chief Commercial Officer-CLIA Sell 40.0 -2,390 -3.24% ✗ $460.4K
Feb 27, 2025 Mar 3, 2025 Stapley Marc CEO Sell 92.5 +12,680 4.12% ✗ $1.9M
Feb 27, 2025 Mar 3, 2025 Febbo Phillip G. Chief Scientific & Med Officer Sell 92.5 +8,163 9.90% ✗ $765.1K
Mar 2, 2025 Mar 3, 2025 Wygant Jonathan VP, Chief Accounting Officer Sell 42.5 -4,301 -10.55% ✗ $149.5K
Feb 27, 2025 Mar 3, 2025 Chambers Rebecca CFO Sell 62.5 +189 0.17% ✗ $787.9K
Feb 27, 2025 Mar 3, 2025 McGuire Annie SVP, General Counsel Sell 40.0 -1,789 -2.44% ✗ $523.8K
Feb 3, 2025 Feb 5, 2025 Chambers Rebecca CFO Sell 52.5 -527 -0.46% ✓ $23.1K
Jan 6, 2025 Jan 8, 2025 EPSTEIN ROBERT S Director Neutral 52.5 - 0.00% ✗ -
Jan 2, 2025 Jan 6, 2025 EASTHAM KARIN Director Sell 7.5 -10,000 -35.09% ✓ $403K
Dec 13, 2024 Dec 17, 2024 Stapley Marc CEO Sell 45.0 -5,590 -1.79% ✓ $242.7K
Dec 4, 2024 Dec 6, 2024 Febbo Phillip G. Chief Scientific & Med Officer Sell 37.5 -3,934 -4.56% ✓ $173.4K
Dec 4, 2024 Dec 6, 2024 McGuire Annie SVP, General Counsel Sell 12.5 -18,699 -20.42% ✓ $823.2K
Dec 2, 2024 Dec 4, 2024 McGuire Annie SVP, General Counsel Sell 42.5 -1,918 -2.05% ✗ $84.6K
Dec 2, 2024 Dec 4, 2024 Leite John Chief Commercial Officer-CLIA Sell 37.5 -2,364 -3.10% ✓ $103.4K
Dec 2, 2024 Dec 4, 2024 Chambers Rebecca CFO Sell 26.3 -10,464 -8.40% ✓ $455.5K
Dec 2, 2024 Dec 4, 2024 Febbo Phillip G. Chief Scientific & Med Officer Sell 40.0 -6,738 -7.24% ✗ $297.3K
Dec 2, 2024 Dec 4, 2024 Wygant Jonathan VP, Chief Accounting Officer Sell 42.5 -2,043 -4.83% ✗ $89.4K
Dec 2, 2024 Dec 4, 2024 Stapley Marc CEO Sell 40.0 -5,748 -1.80% ✗ $253.6K
Nov 27, 2024 Nov 29, 2024 Wygant Jonathan VP, Chief Accounting Officer Sell 22.5 -5,032 -10.63% ✗ $215.8K
Nov 19, 2024 Nov 21, 2024 EASTHAM KARIN Director Sell 7.5 -14,731 -44.33% ✓ $564.8K
Nov 12, 2024 Nov 14, 2024 Chambers Rebecca CFO Sell 22.5 -15,275 -10.93% ✓ $585.7K
Nov 12, 2024 Nov 14, 2024 EPSTEIN ROBERT S Director Sell 7.5 -15,000 -25.17% ✓ $574.8K
Sep 19, 2024 Sep 23, 2024 JONES EVAN/ FA Director Sell 25.0 -5,173 -13.09% ✓ $182.3K
Sep 4, 2024 Sep 6, 2024 Leite John Chief Commercial Officer-CLIA Sell 32.5 -5,479 -6.71% ✓ $163.2K
Sep 2, 2024 Sep 4, 2024 Chambers Rebecca CFO Sell 42.5 -3,464 -2.42% ✗ $109.3K
Sep 2, 2024 Sep 4, 2024 McGuire Annie SVP, General Counsel Sell 42.5 -1,920 -2.01% ✗ $60.6K
Sep 2, 2024 Sep 4, 2024 Wygant Jonathan VP, Chief Accounting Officer Sell 46.3 -1,087 -2.24% ✗ $34.3K
Sep 2, 2024 Sep 4, 2024 Stapley Marc CEO Sell 42.5 -5,748 -1.77% ✗ $181.3K
Sep 2, 2024 Sep 4, 2024 Leite John Chief Commercial Officer-CLIA Sell 46.3 -1,315 -1.58% ✗ $41.5K
Sep 3, 2024 Sep 4, 2024 Miller Thomas F. Director Neutral 90.0 +16,507 100.00% ✗ -